Over the past years, the issue of antithrombotic therapy in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) has essentially focused on the contraposition between triple, i.e., oral anticoagulant (OAC), aspirin and clopidogrel, and double, i.e., OAC and clopidogrel, therapy as the treatment of choice [1, 2] . Whereas uncertainty persists over whether the two regimes are comparably effective, there is no doubt that with triple therapy, the risk of major and/or total bleeding complications is higher than with double therapy [1, 2] . In other words, a higher intensity of antithrombotic therapy, as a result of three antithrombotic agents given in conjunction, is less safe than a lower intensity, as obtained with the combination of only two antithrombotic drugs. Such correspondence appears evident when only warfarin as the OAC and clopidogrel as the P2Y 12 -inhibitor are considered. This may not be the case when OAC safer than warfarin, including the non-vitamin K-antagonist oral anticoagulants (NOAC) dabigatran, apixaban, edoxaban, and rivaroxaban, and P2Y 12 -inhibitors more potent than clopidogrel, including prasugrel and ticagrelor, are given in combination. The intensity, and associated risk of bleeding, of double therapy with less safe agents, such as warfarin and prasugrel or ticagrelor, might actually be higher than that of triple therapy with safer drugs, such as NOAC, aspirin, and clopidogrel. Indeed, in a recent network meta-analysis, where 10,026 patients from WOEST [3], PIO NEER AF-PCI [4 ], RE-DUAL PCI [5 ], and AUGUSTUS [6] trials were included, the risk of major bleeding was shown to be progressively lower with triple therapy of NOAC, aspirin, and clopidogrel; double therapy of warfarin and clopidogrel; and double therapy of NOAC and clopidogrel, respectively, as compared with conventional triple therapy of warfarin, aspirin, and clopidogrel [7] . This means that reducing the overall intensity of antithrombotic therapy, by either keeping the regimen, i.e., triple, but using a safer OAC, i.e., NOAC instead of warfarin, or keeping the OAC, i.e., warfarin, but de-escalating the regimen, i.e., double instead of triple, or changing both the regimen, i.e., double instead of triple, and the OAC, i.e., NOAC instead of warfarin, an increase in safety is obtained. The importance of the overall treatment intensity rather than the regimen per se is further supported by the results of the PIONEER AF-PCI trial [4], where with the same triple therapy regimen of OAC, aspirin, and clopidogrel, the use of very low-dose rivaroxaban 2.5 mg twice daily instead of warfarin was associated with significantly less bleeding events.
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There is currently little data on the individual contribution to the risk of bleeding of the more potent P2Y 12 -inhibitors prasugrel and ticagrelor when used in combined antithrombotic therapies. An increase in hemorrhagic complications has been reported in comparison with clopidogrel with the same antithrombotic regimen [8] , but the safety impact of prasugrel or ticagrelor used for example in double therapy as compared with clopidogrel in triple therapy remains undetermined.
While acknowledging current uncertainties and waiting for further evidence, the different antithrombotic therapies may hypothetically be ranked as outlined in Fig. 1 , based on their overall intensity (and associated risk of bleeding). For the time being, a perspective change from just the number of drugs to be used in combination to a more comprehensive evaluation of the overall treatment intensity is advised when aiming at optimal safety of antithrombotic therapy in AF patients undergoing PCI.
